Memic Innovative Surgery
Last updated: Jul 31, 2026
Memic Innovative Surgery, now operating as Momentis Surgical, develops the Anovo robotic-assisted surgery platform: a compact system with highly articulated, humanoid-inspired instrument arms for constrained minimally invasive procedures. The company remains a private, venture-backed medical-device startup rather than an acquired Medtronic asset.
Visit WebsiteCompany Overview
Memic Innovative Surgery was founded in 2013 in Israel and now presents itself publicly as Momentis Surgical. Its principal product is the Anovo Surgical System, formerly branded Hominis. The platform uses miniature robotic arms whose mechanical architecture is intended to reproduce shoulder-, elbow-, and wrist-like motion inside the body. The design emphasis is high articulation, multi-planar flexibility, and access through a small number of entry points, rather than simply adding more rigid instruments to a large conventional robot. Momentis says the system has a smaller operating-room footprint and a lower cost target than conventional robotic systems, although those economic claims require diligence against actual capital, service, disposable, training, and procedure costs.
The initial commercial wedge is gynecologic surgery. The FDA granted De Novo marketing authorization in 2021 for robotic-assisted transvaginal benign procedures, including hysterectomy and related adnexal procedures. The official indications are narrower than a general claim that Anovo can perform all minimally invasive surgery: the system is intended for trained physicians in an operating-room environment and its safety and effectiveness are tied to specified procedures. Public company updates and secondary reporting indicate expansion toward single-site abdominal and general-surgery applications, including later 510(k) clearances, but the scope, adoption, and clinical economics of those extensions should be verified directly in current regulatory and commercial materials.
The market opportunity is meaningful but difficult. Hospitals and ambulatory surgery centers want robotic assistance that improves dexterity and minimally invasive access without the space, capital, and workflow burden of the dominant multiport systems. Anovo's differentiated geometry could matter in procedures where access path, articulation, triangulation, or preservation of the surgeon's familiar technique is the binding constraint. The substitute set includes Intuitive Surgical's da Vinci installed base, Medtronic Hugo, CMR Surgical's Versius, Medrobotics, and conventional laparoscopy. A smaller footprint alone is unlikely to dislodge incumbents; evidence of repeat purchasing, utilization per installed system, procedure outcomes, reimbursement, consumable margins, service economics, and surgeon-training time is more decision-useful than headline patent counts.
The company has credible productization and regulatory traction, but its financing and operating history also show execution pressure. A proposed 2021 SPAC transaction did not establish a completed public-company exit, and reporting in 2023 described a reduction from roughly 120 employees to about 50 while the company prioritized regulatory work and reduced cash burn. OurCrowd reported a venture-debt opportunity in 2024 and later public issuer records show additional private financing activity; these are evidence of continued capitalization, not proof of sustainable revenue or profitability. The strategic relevance is therefore strongest as a validated compact-surgical-robotics reference and as a live private medtech diligence case, not as a proven defense technology.
For defense and national-security analysis, the dual-use case is real but indirect. Compact teleoperated manipulation, constrained-space dexterity, and surgeon-console control could eventually support remote specialist assistance, mobile surgical teams, or emergency care where operating-room space is limited. However, Anovo is designed and indicated for controlled clinical settings. There is no verified public evidence here of military deployment, ruggedization, autonomous operation, battlefield use, or defense contracts. Any austere-care thesis would require substantial additional work on transportability, sterilization, power, latency, cybersecurity, human factors, maintenance, clinical governance, and regulatory authorization.
Dual-Use Assessment
Anovo's compact articulated manipulators and teleoperated control architecture have substantive commercial use in minimally invasive surgery and plausible security use in remote specialist assistance or space-constrained emergency medicine. The defense relevance remains indirect and unvalidated: no public evidence in this record demonstrates military deployment, ruggedization, battlefield operation, or defense contracting.
Strategic Fit Assessment
Priority signal means this entry may be worth researching within the Claw & Talon thesis. It does not mean investable, suitable, endorsed, available, or likely to produce returns.
The company is a live private startup with a differentiated surgical-robotics architecture, regulatory traction, and a credible strategic fit for compact precision medicine. The positive signal is constrained by financing needs, workforce contraction, procedure-specific indications, uncertain utilization economics, and the absence of verified defense deployment; diligence should focus on runway, installed systems, recurring procedure volume, reimbursement, regulatory milestones, and evidence that the platform can expand beyond its initial gynecologic wedge.
Strategic Value to U.S.-Israel Alliance
Momentis is strategically valuable as an Israeli deep-tech medtech company demonstrating a different path to surgical-robotics miniaturization: highly articulated instruments in a smaller footprint. That architecture can inform future remote-care and mobile-medical concepts, but the immediate value is commercial clinical capability. Defense relevance should be treated as an option requiring ruggedization, secure communications, clinical validation, and operational partners rather than as an existing military capability.
Key Technologies
- Miniaturized articulated robotic instrument arms
- Shoulder-elbow-wrist-inspired kinematics
- 360-degree and multi-planar instrument articulation
- Surgeon-console teleoperation and instrument control
- Natural-orifice and single-site minimally invasive access
- Procedure-specific surgical instruments and electrosurgical tools
- Compact operating-room system integration
Use Cases & Applications
- Robotic-assisted benign hysterectomy
- Transvaginal gynecologic procedures
- Salpingectomy, oophorectomy, adnexectomy, and ovarian cyst removal
- Single-site or limited-access abdominal procedures where cleared
- Ambulatory surgery-center robotic assistance
- Remote specialist support for emergency surgical teams, subject to future validation
- Compact surgical capability for constrained or austere medical environments, subject to ruggedization and authorization
Sources and verification
This profile is based on public-source research, Claw & Talon curation, and editorial judgment. Inclusion does not imply endorsement, partnership, investment, or a recommendation to transact. Readers should still confirm current status, customers, funding, and product claims before relying on this profile. The editorial policy explains how profiles are researched, where automated drafting is used, and how corrections work.
This record lists 11 public references used for company identity, status, positioning, or material-claim review.
Public sources
The links below are visible public references used for source discipline around company identity, status, funding, customer, acquisition, public-company, or other material claims where available.
- momentissurgical.com Public source used for profile verification.
- momentissurgical.com Public source used for profile verification.
- momentissurgical.com Public source used for profile verification.
- momentissurgical.com Public source used for profile verification.
- accessdata.fda.gov Public source used for profile verification.
- accessdata.fda.gov Public source used for profile verification.
- calcalistech.com Public source used for profile verification.
- ourcrowd.com Public source used for profile verification.
- nasaaefd.org Public source used for profile verification.
- LinkedIn company page Public source used for profile verification.
- Official website
- Profile update timestamp Last updated in the Claw & Talon database on Jul 31, 2026.
Investor Lens
What this entry is
Private startup
Why it may matter
Memic Innovative Surgery may matter as a Robotics & Autonomy entry with not currently an investable standalone company for Israeli technology research.
How an independent investor should read this
Not currently an investable standalone company. Read this profile as a starting point for independent verification, not as a recommendation or suitability assessment.
Evidence to verify
- Verify current status
- Verify traction
- Verify cap table/funding
- Verify technical claims
- Verify regulatory/export-control issues
- Verify customer concentration
Main investor questions
- Is the company currently active, independently financeable, and raising or not raising on terms you can verify?
- What customer, revenue, product, and technical evidence supports the company story?
- What valuation, cap table, rights, and follow-on assumptions would govern any private exposure?
- Does the dual-use claim map to actual commercial and government/defense/resilience buyer evidence?
- What evidence would change the thesis or show that the profile is stale?
What not to infer
- Inclusion does not imply endorsement.
- Inclusion does not imply allocation availability or current fundraising.
- Scores do not indicate investment suitability or expected returns.
- Strategic importance does not automatically imply venture return potential.
Diligence questions
- What evidence verifies Memic Innovative Surgery's current customer traction, deployment status, and revenue concentration?
- Which technical claims are independently demonstrable today, and which remain roadmap or pilot-stage assertions?
- Where does the product create real defense, intelligence, critical-infrastructure, or emergency-response value beyond ordinary commercial adoption?
- What export-control, supply-chain, manufacturing, or classified-market constraints could affect U.S. and allied adoption?
- What would disconfirm the priority signal: weak customer references, thin technical differentiation, poor capital efficiency, or limited allied-market access?
Related sector
See the Robotics & Autonomy sector page for market context, related subcategories, and other Israeli companies in this part of the database.
Related companies
Need a diligence readout?
Use the profile and related checklists as a starting point. If the decision needs more context, request a company screen, founder-call prep, diligence memo, or sector readout.